![]() We’re far from the end of the pandemic, and Novavax could provide the incremental vaccine doses the world needs. That said, outside of the U.S., tremendous opportunity lies for Novavax to grab market share and deliver vaccines. is the key catalyst that’s driving investor interest in this stock. 2 Stock-Split AI Growth Stocks to Buy Before They Soar 53 and. The company didnt announce any new developments. However, this article highlights a number of other headwinds many seem to think are unwarranted.Ĭurrently, Novavax’s approval process in the U.S. Shares of Novavax (NVAX 2.62) were sinking 9.6 as of 11:47 a.m. Some supporters did note concern with Novavax’s self-imposed deadline of an FDA filing before the end of the year. Unsurprisingly, these concerns were met with a certain amount of vitriol by Novavax supporters on social media. A POLITICO article released this morning highlighted concerns not only with respect to Novavax’s ability to get its drug approved by the FDA, but also concerns around the production capacity for this vaccine maker. by the end of January 2022.īesides the delay on the FDA filing, there’s another catalyst driving NVAX stock today. Traders could go long NVAX at current levels risking to 145. ![]() In terms of timeline, that means Novavax now intends to file for emergency-use authorization in the U.S. Bottom-line strategy: Some analysts may wait for a breakout over the September high to go long NVAX but I like the risk/reward set up now. ![]() Instead, the company announced today that it has filed its last data packages with U.S. ![]() Many were hopeful that by the end of the year, the company would file with the FDA for emergency-use authorization. Leading into today, investors have been getting antsy with Novavax. What’s Behind Today’s Decline in NVAX Stock ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |